DOCSLIB.ORG

Phenothiazine Poisoning a Review of 48 Cases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenothiazine Poisoning a Review of 48 Cases Refer to: Barry D, Meyskens FL Jr, Becker CE: Phenothiazine poison- ing-A review of 48 cases. Calif Med 118:1-5, Jan 1973 California Medicine THE WESTERN JOURNAL OF MEDICINE Phenothiazine Poisoning A Review of 48 Cases DANIEL BARRY, B.A., FRANK L. MEYSKENS, JR., M.D., AND CHARLES E. BECKER, M.D., San Francisco * Of 48 cases of phenothiazine poisoning that were analyzed, 34 were attributed to stuicide attempts, nine to accidental ingestion, and five to drug reactions. As outpatient treatment of schizophrenia increases, cases of over- dose with phenothiazine drugs may be expected to increase also. The prescribing of multiple phenothiazines and antidepressants is probably contributory to the occurrence of mixed drug ingestions. The symptoms and signs of phenothiazine poisoning are largely predictable if the atropine-like, alpha-blocking, quinidine-like, and extrapyramidal actions of phenothiazines are appreciated, Unexplain- able tachypnea and paradoxical miosis were noted in severe cases. In one case in the study phenothiazine intoxication was present in the newborn infant of a schizophrenic mother. PHENOTHIAZINES ARE BECOMING household drugs tionable advertising campaigns advocating phe- in Califomnia. The closing of state hospitals with nothiazines for the treatment of a wide variety the concomitant institution of mass outpatient of ailments have made these drugs generally treatment of chronic schizophrenics through com- available. The high incidence of schizophrenia munity mental health centers, and recent quesv in young adulthood and the increasing suicide From the Detoxification Unit, San Francisco General Hospital, and rate in this age group" suggest that phenothia- the Department of Clinical Pharmacology, University of California, San Francisco. zine poisoning will become increasingly common. Submitted June 14, 1972. Two large literature reviews of psychotropic over- At the time of this study Mr. Barry and Dr. Meyskens were third and fourth year students respectively attending the University of Cali- dose have appeared recently, but the cited case fornia, San Francisco. Reprint requests to: C. E. Becker M.D., Director, Detoxification studies were small and seemed largely to involve Unit, San Francisco General I4ospitaf, 1001 Potrero Avenue, San Fran- cisco, Ca. 94110. only severe ingestion illness.2,3 An examination CALIFORNIA MEDICINE I The Western Journal of Medicine of the problem of phenothiazine overdosage was TABLE l.-General Data on 48 Cases of Phenothia- therefore undertaken. To that end the presenta- zine Poisoning tion, management, and outcome of 48 consecutive Suicide Attempts Accidental Ingestions cases of phenothiazine poisoning were retrospec- Total 34 9 tively analyzed. single drug 19 7 multiple drug 15 2 Clinical Material Sex San Francisco General Hospital, a 1200-bed male 14 7 facility affiliated with the University of California female 20 2 Medical Center, recently instituted a computer Race white 32 2 card index according to final major diagnosis of non-white 2 7 all admissions. All charts (except two which were unavailable) coded under "tranquilizer tox- Marital Status married 5 icity" from October of 1969 to May of 1971 were single 29 48 studied, and cases involving phenothiazine Age (yrs) Age (yrs) overdosage as the major contributing event lead- Less than 26 21 Less than 5 8 ing to admittance to hospital were selected for More than 26 13 More than 5 1 further analysis. Included in the cases studied were suicide attempts, accidental drug ingestions, and serious drug reactions. The charts were analyzed for recorded drug type and amount, TABLE 2.-Phenothiazines Involved in Overdoses Phenothiaztne With Other sex, age, race, marital status, vital signs, eye signs, Phenothiazine* only drugs** mental status, treatment, complications, and Chlorpromazine (Thorazine®) 16 8 length of stay. Since many charts were incom- Trifluoperzine ( Stellazine®) 4 7 plete, complete information was not available on Thioridazine (Mellaril®) 3 2 every patient. Because definite toxicology reports Promazine (Sparine®) 1 0 were generally not recorded, objective confirma- Unknown 2 0 tion of the history was often impossible. In all *in amounts ranging from 200 to 500 mg four cases in which it was done, Phenostix testing **included Elavil®4, alcohol2, Artane®2, Librium® and 16 other of the urine was positive-in one case after dilu- drugs in single instances tion of the urine. TABLE 3.-Initial Vital Signs 'in 26* Cases of Over- Results dose with Phenothiazine Only Sociology (Table 1). Suicide gestures were No. of No. of most common in single, young, white women. Patients Patients Multiple drug ingestion was common (15 of Temperature 980 or less 10 990 or more 5 34 cases). Accidental ingestion seemed to in- Pulse 700 or less 2 1000 or more 10 volve the non-white community disproportionate- Respiration 120 or less 0 250 or more 6 ly. Phenothiazines of many varieties were in- Blood Pressure systolic 1100 or less 3 1300 or more 4 volved (Table 2). diastolic 700 or less 12 900 or more 1 Vital signs (Table 3). Phenothiazine poison- *Complete data absetit in many cases ing is characterized by a tendency toward hypo- thermia, tachyeardia, tachypnea, and decreased diastolic blood pressure. TABLE 4.-Initial Mental Status of 43 Patients for Mental status (Table 4). A clear tendency to- Whom Data Were Available ward greater obtundation was noted in cases of mixed drug overdoses. Eye signs. No trend was noted in the mixed drug overdoses. However, in thfe 12 reported .4~~~~.0 cases of pure phenothiazine overdoses in which With phenothiazine only 2 14 10 2.2 0 information was available (the more serious in- With other drugs 5 9 3 2.8 6 2 JANUARY 1973 * 118 * I gestions) pupil size in nine cases was "small" (3 thiazine-poisoned patient. Although unavailabil- mm or less). Only in three cases were the pupils ity of toxicological data prevented confirmation greater than 4 mm in diameter. of the history and the ruling out of mixed, occult ingestions, which are known to occur frequently,5 Treatment distinct trends were evident in the patients said to have taken only phenothiazines. The hypo- Treatment included administration of ipecac thermia, tachyeardia, and decreased diastolic (15 cases), gastric lavage (nine cases), intrave- blood pressure can be directly attributed to al- nous hydration (25 cases), and intravenous di- pha-blocking and anticholinergic effects. Hypo- phenylhydramine (Benadryl®) in three cases. thermia can be relieved by appropriate covering6 Methylphenidate (Ritalin®) had been given to while the decreased blood pressure, largely sec- two children at other hospitals before they were ondary to alpha-blockade, can be easily managed transferred to San Francisco General. Interest- by putting the patient in the reverse Trendelen- ingly intubation was not needed in any case in burg position, by volume expansion, or in more which only phenothiazine was ingested, but it extreme cases by use of direct-acting alpha stim- was required in six cases of mixed overdose. ulators.24,7 Epinephrine with its mixed alpha and beta effect and isoproterenol hydrochloride Prognosis (IsuprelR) with its largely beta action are there- None of the 48 patients died and half of them fore contraindicated. The tachypnea noted in needed less than 24 hours in hospital. The aver- these cases has not been noted previously (see age stay of the other 24 was 3.4 days and the reference 4), and an explanation is difficult to longest was 31 days. Potentially serious compli- formulate. Small pupil size noted in 75 percent cations were noted in 17 of the 24 patients with of the patients who had taken only phenothiazine the longer stay in hospital. (Tables 5 and 6). was a surprising finding, and it was observed only in the most severely poisoned. This phe- Discussion nomenon may represent an overriding of the atro- pinic effect by the alpha-blocking effect of phe- In addition to their antipsychotic activity, the nothiazines and may serve as a clinical clue to phenothiazines possess significant anticholinergic, the severity of the overdose. This important ob- alpha-adrenergic blocking, quinidine-like and ex- servation requires further confirmation. The importance of these trapyramidal activity.4 Prolonged QT interval which reverted sponta- modes of action becomes evident in the pheno- neously was noted in three cases. Although this is not well documented, persistent widening and QRS changes apparently can be treated effectively TABLE 5.-Complications of Phenothiazine Overdose with diphenylhydantoin (Dilantin®l) 8 The in- creased incidence of sudden death in phenothia- C~~~~~~~~~~~~~~~~~~ 5 zine-treated patients may be related to this 0~~~~~~~~~~~~~ K quinidine-like effect,9 and certainly an initial .sCA ,5 O ,, _~~ cardiogram is indicated for all phenothiazine- -9 .XC Chlorpromazine seizure 1 1.3 TABLE 6.-Phenothiazine Reactions (Thorazine®) prolonged QT interval 1 16* distended bladder 1 3 Description of disorder Tranquilizer aspiration pneumonia --- 1 ) Respiratory depression in the new- Fluphenazine Thioridazine ataxia 1 11.8 born of a schizophrenic mother (Prolixin®) (Mellaril®) aspiration pneumonia 1 _- 2) Photosensitivity reaction-vessicles Chlorpromazine Prochlorpenajine ataxia-rigidity 1 33.4 of hands and face (Thorazine®) (Compazine®) 3) Inability to open mouth after treat- Chlorpromazine Triflupromazin athetoid movement 1 1.3 ment of heroin withdrawal (Stellazine®)O~~~~, 4) Drug fever (105°F), with history ChlorpromazineX Unknown rigidity 1 of allergy prolonged QT 2 16 5) Cogwheel rigidity Thioridazine *As noted by David, Bartlett and Termoni10 (Mellaril®) CALIFORNIA MEDICINE 3 The Western Journal of Medicine poisoned patients. Although it does sometimes occur, death is a rarity in such cases.10 The low mortality rate may reflect at least in part a tend- ency to attribute late deaths to other causes. An analysis of potential complications as noted in this study might indicate much more frequent serious sequelae to drug ingestion than are gen- erally reported in other studies.1"2 It is of inter- est, however, that all patients with complications in the present study recovered.
Load more

Recommended publications
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics
    CHAPTER 15 _ Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics By FREDERICK B. CHARAT AN, M.D. OF THE MANY studies carried out with lysergic acid diethylamide in the last 15 years, relatively few have dealt with regressed schizophrenics. Most workers have used comparatively small doses of LSD. Some gave up to 600 gamma orally. Others reported the effects of up to 500 gamma intra- muscularly, 180 gamma intravenously and 60 gamma intrathecally in small series of cases. Several investigators agreed that in chronic schizophrenics higher doses of LSD than those administered to undeteriorated schizo- phrenics and nonpsychotics have been required to produce psychic effects. Apart from the slight response of chronic schizophrenics to doses of LSD which lead to marked and characteristic effects in other subjects, tolerance to the drug seems to develop in as brief a period as three days. These differences in response to LSD pose some interesting problems. Is the lack of response in chronic schizophrenics merely an apparent one caused by their inability to communicate their inner experiences? Is it due to the development of some immune state connected with biochemical alter- ations produced during the psychosis? Is it the reflection of a metabolic difference between schizophrenics and non-schizophrenics? May it be a general manifestation of schizophrenic underresponsiveness to virtually any stress, once the chronic stagnant phase of the psychosis has been reached? Clear answers to all these questions cannot yet be given. The present investi- gation was undertaken to examine further the responses of chronic schizo- phrenics to large doses of LSD and also to observe the effect of other drugs upon this response.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]
  • Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary
    396 Journal of Health Science, 50(4) 396–406 (2004) Preparation of Metabolites N-oxides from parent drug could be confirmed when the collisional energy was decreased to 10 eV. 1H- and by Chemical Reaction: 13C-NMR spectral data confirmed the structure of the Conversion of Antipsychotic prepared mianserin N-oxide to be 2-oxide. In conclu- sion, a simple and rapid preparation method for oxide Phenothiazines to their metabolites of phenothiazines and tertiary amino cy- Sulfoxides and Tertiary clic antidepressants available as analytical standards was established. Amino Cyclic Key words —–— metabolite, chemical preparation, ox- Antidepressants ide, phenothiazine, cyclic antidepressants, mass spectros- to their N-Oxide with copy Hydrogen Peroxide Using Titanosilicate INTRODUCTION Catalyst The identification and quantification of drugs Akira Ogamo* and Mariko Fukumoto ingested into human bodies require comprehensive information covering the target drugs themselves and School of Pharmaceutical Sciences, Kitasato University, their metabolites. To carry out a quantitative analy- Shirokane 5–9–1, Minato-ku, Tokyo 108–8641, Japan sis, the standard substances of metabolites are es- (Received March 5, 2004; Accepted April 11, 2004) sential. Some important metabolites can be obtained as commercial products, but many metabolites, es- The aim of this study was to establish a prepara- pecially those of new drugs, are difficult to obtain tion method needed to analyze the metabolites of an as standard samples. These problems have been analytical procedure for antipsychotic phenothiazines solved by using experimental animals or isolated and tertiary amino cyclic antidepressants by chemical enzyme systems originating from biological mate- reaction. These drugs were oxidized to their sulfoxide rials.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • Trilafon Tablets & Trilafon Injection Final Printed Labeling
    PAGE 1 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 1 TRILAFON Ò 2 brand of perphenazine, USP 3 Tablets, 4 Injection 5 6 DESCRIPTION TRILAFON products contain perphenazine, USP (4-[3-(2- 7 chlorophenothiazin-10-yl)propyl]-1-piper-azineethanol), a piperazinyl phenothiazine 8 having the chemical formula, C21H26CIN3OS. They are available as Tablets, 2, 4, 9 8, and 16 mg; and Injection, perphenazine 5 mg per 1 mL. 10 The inactive ingredients for TRILAFON Tablets, 2, 4, 8, and 16 mg, include: 11 acacia, black iron oxide, butylparaben, calcium phosphate, calcium sulfate, 12 carnauba wax, corn starch, lactose, magnesium stearate, sugar, titanium dioxide, 13 and white wax. The inactive ingredients for TRILAFON Injection include: citric 14 acid, sodium bisulfite, sodium hydroxide, and water. 15 ACTIONS Perphenazine has actions at all levels of the central nervous system, 16 particularly the hypothalamus. However, the site and mechanism of action of 17 therapeutic effect are not known. 18 CLINICAL PHARMACOLOGY Pharmacokinetics: Following oral administration 19 of TRILAFON® Tablets, mean peak plasma perphenazine concentrations were 20 observed between 1 to 3 hours. The plasma elimination half-life of perphenazine 21 was independent of dose and ranged between 9 and 12 hours. In a study in which 22 normal volunteers (n=12) received TRILAFON 4 mg q8h for 5 days, steady-state 23 concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax 24 and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are 25 listed below: 26 ParameterPerphenazine 7-Hydroxyperphenazine 27 Cmax (pg/mL) 984 (43) 509 (25) 28 Cmin (pg/mL) 442 (76) 350 (56) 1 PAGE 2 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 29 Peak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours 30 with a terminal phase half-life ranging between 9.9 to 18.8 hours.
    [Show full text]
  • Psychotropic Medication Audit Criteria and Guidelines
    Psychotropic Medication Audit Criteria and Guidelines Fluphenazine decanoate (Prolixin®, decanoate) and Haloperidol decanoate (Haldol®, decanoate) PEFC Approved: July 2021 Indications Label: ● Patients with schizophrenia who require prolonged parenteral antipsychotic therapy Off label: • Schizoaffective disorder Black Box Warning ● Increased mortality in elderly patients with dementia-related psychosis Contraindications ● Severe central nervous system depression or comatose states from any cause ● Hypersensitivity to the drug or derivatives ● Haloperidol decanoate Parkinson’s disease Dementia with Lewy bodies ● Fluphenazine decanoate Suspected or established subcortical brain damage Receiving large doses of hypnotics Blood dyscrasias Hepatic disease Warnings and Precautions ● Severe cardiovascular disorders ● Concomitant use with other CNS depressants ● Diagnosis of a seizure disorder or history of seizures ● Haloperidol only 1 Texas Health and Human Services ● hhs.texas.gov Antipsychotics-decanoates Must not be administered intravenously. QTc prolonging conditions (electrolyte imbalances, drugs known to prolong QTc, underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome) Leukopenia/neutropenia Thyrotoxicosis Myasthenia gravis Bipolar disorder ● Fluphenazine only History of cholestatic jaundice, dermatoses, or other allergic reactions to phenothiazine derivatives Reduced amounts of anesthetics or CNS depressants may be necessary Effects of atropine may be potentiated Use caution in patients exposed
    [Show full text]
  • Piportil Depot 50 Mg/Ml
    Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Piportil Depot 50 mg/ml. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pipotiazine palmitate 50 mg/ml. For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Depot injection. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the maintenance treatment of schizophrenia and paranoid psychoses and prevention of relapse, especially where compliance with oral medication is a problem 4.2 Posology and method of administration Patients should be stabilised on Piportil Depot under psychiatric supervision. Administration should be by deep intramuscular injection into the gluteal region. Wide variation of response can be expected. The following dosage recommendations are suitable for either indication. Adults: Initially 25mg should be given to assess the response of the patient to the drug. Further doses should be administered at appropriate intervals, increasing by increments of 25 or 50 mg until a satisfactory response is obtained. In clinical practice, Piportil Depot has been shown to have a long duration of action, allowing intervals of 4 weeks between injections for maintenance therapy. Dosage should be adjusted under close supervision to suit each individual patient in order to obtain the best therapeutic response compatible with tolerance. The duration of action depends on the dose administered, allowing dosage intervals to be varied to suit individual circumstances. Most patients respond favourably to a dose of 50-100 mg every 4 weeks, the maximum recommended dose is 200 mg every four weeks. Elderly : Neuroleptics should be used cautiously in the elderly: A reduced starting dose is recommended, ie 5-10 mg might be considered.
    [Show full text]
  • DOMASYS Standard
    New Zealand Data Sheet 04 December 2018 Neulactil-periciazine DATA SHEET 1 NEULACTIL TABLETS Neulactil 2.5 mg tablets Neulactil 10 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Periciazine 2.5mg Periciazine 10mg Excipients with known effect: lactose monohydrate and wheat starch For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Neulactil tablets 2.5 mg: yellow, scored, marked NEULACTIL 10 mg: yellow, scored, marked 10 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Periciazine is indicated: 1. In adults with schizophrenia or other psychoses, for the treatment of symptoms or prevention of relapse. 2. In anxiety, psychomotor agitation, violent or dangerously impulsive behaviour. periciazine is used as an adjunct to the short-term management of these conditions. Periciazine tablets are not recommended for children (see Section 4.3 and 4.4). neulactil-ccsiv4-dsv11-04dec18 Page 1 New Zealand Data Sheet 04 December 2018 Neulactil-periciazine 4.2 DOSE AND METHOD OF ADMINISTRATION Dosage requirements vary with the individual and the severity of the condition being treated. Initial dosage should be low with progressive increases until the desired response is obtained, after which dosage should be adjusted to maintain control of symptoms. Severe conditions (Indication 1) Adults Initially 75 mg per day in divided doses. Dosage should be increased by 25 mg per day at weekly intervals until optimum effect is achieved. Maintenance therapy would not normally be expected to exceed 300mg per day. Elderly Initially 15-30 mg per day in divided doses. If this is well tolerated the dosage may be increased if necessary for optimum control of behaviour.
    [Show full text]
  • Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper
    No. 6] Proc. Japan Acad., 46 (1970) 583 136. Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper By Tetsukichi NIwAGudHTand Takako INOUE National Research Institute of Police Science, Tokyo (Comm.by TanemotoFURUHATA. M.J. A.,June 12, 1970) Various analytical methods for lysergic acid diethylamide (LSD) have been reported and some of them are based on a specific colora- tion of LSD by p-dimethylaminobenzaldehyde. Look has suggested a method for field screening test of LSD using this reagent.i~ It is purpose of this paper to establish a method for screening of LSD by test paper. Experimental. Material. The samples used in this experiment are as follows. LSD, seven kinds of antifebrics and analgesics, eighteen kinds of hypnotics, sixteen kinds of tranquilizers, two kinds of antihistaminics, seven kinds of local anaesthetics, twenty-nine kinds of other drugs, twenty-six kinds of alkaloids and narcotics, and eight kinds of amino acids. Forms of LSD and drugs used are as follows. LSD: pure powder, tablet containing 50 p g of LSD (90% of lactose, 7 % of starch and 3% of talc are mixed, ethanol solution containing 50 pg of LSD is added, the solvent is evaporated and tablet with 8 mm in diameter and 2 mm in thickness is prepared), and sugar cube con- taining 40 pg of LSD (6.3 g of sugar cube is soaked in ethanol solu- tion containing 40 pg of LSD and air-dried). Drugs : pure powder. Reagent. 1. Preparation of test paper. Filter paper (Toyo Roshi No. 131) is soaked in a solution of 2 % p-dimethylamino- benzaldehyde in ethanol, dried in air and cut into strips for test paper.
    [Show full text]
  • Antipsychotics-Children-Surveillance
    AHRQ Comparative Effectiveness Review Surveillance Program CER #39: First & second generation antipsychotics for children and young adults Original Release Date: February, 2012 Surveillance Report: November, 2012 Surveillance Report: October, 2014 Summary of Key Findings from Surveillance Reports: • For Key Question 1, studies were identified suggesting that conclusions related to the effectiveness of Second Generation Antidepressants (SGA) for anorexia nervosa are out of date, that conclusions related to the comparative effectiveness of First Generation Antidepressants (FGA) and SGAs are possibly out of date, that the conclusion of no difference between SGAs and placebo for aggression is possibly out of date, that the strength of evidence (SOE) for SGAs and improvement on mania scales may possibly increase from low to moderate, and the SOE regarding risperidone and reduction in problem behavior may have increased. • For Key Question 2, conclusions related to cardiovascular events and weight gain, and the tolerability of molidone hydrochloride are possibly out of date, and the SOE for additional adverse events may possibly increase from moderate to high. • For Key Question 3, the conclusion on the safety and tolerability of FGAs vs. SGAs is possibly out of date. • For Key Question 4, conclusions related to individuals with comorbid disorders are possibly out of date. Signal Assessment: The signals examined in this surveillance assessment suggest that the original CER is possibly out of date. i Authors: Karli Kondo Maya O’Neil Shammarie Mathis Ryan McKenna Kelly Vander Ley Johanna Anderson Mark Helfand Conflict of Interest: None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
    [Show full text]